These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 8044962

  • 1. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial.
    Faxon DP, Spiro TE, Minor S, Coté G, Douglas J, Gottlieb R, Califf R, Dorosti K, Topol E, Gordon JB.
    Circulation; 1994 Aug; 90(2):908-14. PubMed ID: 8044962
    [Abstract] [Full Text] [Related]

  • 2. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.
    Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R.
    J Am Coll Cardiol; 1996 Nov 15; 28(6):1437-43. PubMed ID: 8917255
    [Abstract] [Full Text] [Related]

  • 3. [Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study].
    Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia E, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R, Karsch KR.
    Z Kardiol; 1997 Aug 15; 86(8):581-91. PubMed ID: 9417748
    [Abstract] [Full Text] [Related]

  • 4. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.
    Faxon DP.
    J Am Coll Cardiol; 1995 Feb 15; 25(2):362-9. PubMed ID: 7829789
    [Abstract] [Full Text] [Related]

  • 5. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.
    Lablanche JM, McFadden EP, Meneveau N, Lusson JR, Bertrand B, Metzger JP, Legrand V, Grollier G, Macaya C, de Bruyne B, Vahanian A, Grentzinger A, Masquet C, Wolf JE, Tobelem G, Fontecave S, Vacheron A, d'Azemar P, Bertrand ME.
    Circulation; 1997 Nov 18; 96(10):3396-402. PubMed ID: 9396433
    [Abstract] [Full Text] [Related]

  • 6. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
    Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, Branzi A, Shepherd J, Suryapranata H, de Feyter PJ, Melkert R, van Es GA, Pfister PJ.
    Eur Heart J; 1999 Jan 18; 20(1):58-69. PubMed ID: 10075142
    [Abstract] [Full Text] [Related]

  • 7. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome.
    Brack MJ, Ray S, Chauhan A, Fox J, Hubner PJ, Schofield P, Harley A, Gershlick AH.
    J Am Coll Cardiol; 1995 Oct 18; 26(4):947-54. PubMed ID: 7560622
    [Abstract] [Full Text] [Related]

  • 8. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
    Bertrand ME, McFadden EP, Fruchart JC, Van Belle E, Commeau P, Grollier G, Bassand JP, Machecourt J, Cassagnes J, Mossard JM, Vacheron A, Castaigne A, Danchin N, Lablanche JM.
    J Am Coll Cardiol; 1997 Oct 18; 30(4):863-9. PubMed ID: 9316510
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or on clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
    Hermans WR, Rensing BJ, Foley DP, Deckers JW, Rutsch W, Emanuelsson H, Danchin N, Wijns W, Chappuis F, Serruys PW.
    J Am Coll Cardiol; 1992 Oct 18; 20(4):767-80. PubMed ID: 1388181
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
    Serruys PW, Klein W, Tijssen JP, Rutsch W, Heyndrickx GR, Emanuelsson H, Ball SG, Decoster O, Schroeder E, Liberman H.
    Circulation; 1993 Oct 18; 88(4 Pt 1):1588-601. PubMed ID: 8403306
    [Abstract] [Full Text] [Related]

  • 11. Clinical characteristics and angiographic follow-up of patients undergoing early or late repeat dilation for a first restenosis.
    Bauters C, Lablanche JM, McFadden EP, Leroy F, Bertrand ME.
    J Am Coll Cardiol; 1992 Oct 18; 20(4):845-8. PubMed ID: 1527294
    [Abstract] [Full Text] [Related]

  • 12. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES).
    Jørgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, Hansen J, Webb J, Buller C, Goulet G, Erikssen J, Thaulow E.
    J Am Coll Cardiol; 2000 Mar 01; 35(3):592-9. PubMed ID: 10716459
    [Abstract] [Full Text] [Related]

  • 13. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP, Bonnier H, Jackson G, Macaya C, Shepherd J, Vrolix M, Serruys PW.
    Am J Cardiol; 1994 May 26; 73(14):50D-61D. PubMed ID: 8198025
    [Abstract] [Full Text] [Related]

  • 14. Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups.
    Foley DP, Melkert R, Umans VA, de Jaegere PP, Strikwerda S, de Feyter PJ, Serruys PW.
    Eur Heart J; 1995 Oct 26; 16(10):1331-46. PubMed ID: 8746901
    [Abstract] [Full Text] [Related]

  • 15. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Circulation; 1992 Jul 26; 86(1):100-10. PubMed ID: 1535568
    [Abstract] [Full Text] [Related]

  • 16. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT).
    Serruys PW, Rutsch W, Heyndrickx GR, Danchin N, Mast EG, Wijns W, Rensing BJ, Vos J, Stibbe J.
    Circulation; 1991 Oct 26; 84(4):1568-80. PubMed ID: 1833088
    [Abstract] [Full Text] [Related]

  • 17. Restenosis rate after multiple percutaneous transluminal coronary angioplasty procedures at the same site. A quantitative angiographic study in consecutive patients undergoing a third angioplasty procedure for a second restenosis.
    Bauters C, Mc Fadden EP, Lablanche JM, Quandalle P, Bertrand ME.
    Circulation; 1993 Sep 26; 88(3):969-74. PubMed ID: 8353924
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.
    Maresta A, Balducelli M, Latini R, Bernardi G, Moccetti T, Sosa C, Barlera S, Varani E, Ribeiro da Silva EE, Monici Preti A, Maggioni AP, STARC II Investigators.
    Catheter Cardiovasc Interv; 2005 Mar 26; 64(3):375-82. PubMed ID: 15736248
    [Abstract] [Full Text] [Related]

  • 20. Usefulness of Nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). NIsoldipine in COronary artery disease in LEuven.
    Dens JA, Desmet WJ, Coussement P, De Scheerder IK, Kostopoulos K, Kerdsinchai P, Supanantaroek C, Piessens JH.
    Am J Cardiol; 2001 Jan 01; 87(1):28-33. PubMed ID: 11137829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.